Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 664-669

  White, Phillip J ^a,b   St Pierre, Philippe ^a,b   Charbonneau, Alexandre ^a,b   Mitchell, Patricia L ^a,b   St Amand, Emmanuelle ^a,b   Marcotte, Bruno ^a,b   Marette, André ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CYTOKINE; DIHYDROXYDOCOSA HEXAENOIC ACID; FATTY ACID DERIVATIVE; GLUCOSE; INSULIN; INTERLEUKIN 6; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG SELECTIVITY; GLUCONEOGENESIS; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

MUS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOCOSAHEXAENOIC ACIDS; ETHANOL; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; INTERLEUKIN-6; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION;

EID: 84902135489     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3549     Document Type: Article

References (33)

1. White, P.J., Arita, M., Taguchi, R., Kang, J.X. & Marette, A. Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes 59, 3066-3073 (2010).
2. Serhan, C.N. et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176, 1848-1859 (2006). (Pubitemid 43134330)
3. Chen, P. et al. Full characterization of PDX, a neuroprotectin/protectin D1 isomer, which inhibits blood platelet aggregation. FEBS Lett. 583, 3478-3484 (2009).
4. Awazawa, M. et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 13, 401-412 (2011).
5. Pedersen, B.K. & Febbraio, M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 88, 1379-1406 (2008).
6. Pedersen, B.K. & Febbraio, M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8, 457-465 (2012).
7. Stanford, K.I. et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest. 123, 215-223 (2013).
8. Sag, D., Carling, D., Stout, R.D. & Suttles, J. Adenosine 5?-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181, 8633-8641 (2008).
9. Inoue, H. et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 3, 267-275 (2006).
10. Inoue, H. et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 10, 168-174 (2004). (Pubitemid 38524887)
11. Carey, A.L. et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55, 2688-2697 (2006). (Pubitemid 44923666)
12. Kelly, M., Gauthier, M.S., Saha, A.K. & Ruderman, N.B. Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 58, 1953-1960 (2009).
13. Kelly, M. et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem. Biophys. Res. Commun. 320, 449-454 (2004). (Pubitemid 38798888)
14. Clria, J., Dalli, J., Yacoubian, S., Gao, F. & Serhan, C.N. Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J. Immunol. 189, 2597-2605 (2012).
15. Jov?, M., Planavila, A., Laguna, J.C. & Vαzquez-Carrera, M. Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor κB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology 146, 3087-3095 (2005). (Pubitemid 41002818)
16. Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015-3025 (2006). (Pubitemid 44684486)
17. Wunderlich, F.T. et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12, 237-249 (2010).
18. Pedersen, B.K. & Febbraio, M.A. Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102, 814-816 (2007).
19. Mauer, J. et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423-430 (2014).
20. Gray, S.R., Ratkevicius, A., Wackerhage, H., Coats, P. & Nimmo, M.A. The effect of interleukin-6 and the interleukin-6 receptor on glucose transport in mouse skeletal muscle. Exp. Physiol. 94, 899-905 (2009).
21. Tweedell, A. et al. Metabolic response to endotoxin in vivo in the conscious mouse: role of interleukin-6. Metabolism 60, 92-98 (2011).
22. Pilon, G., Dallaire, P. & Marette, A. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J. Biol. Chem. 279, 20767-20774 (2004). (Pubitemid 38656473)
23. Centeno-Baez, C., Dallaire, P. & Marette, A. Resveratrol inhibition of inducible nitric oxide synthase in skeletal muscle involves AMPK but not SIRT1. Am. J. Physiol. Endocrinol. Metab. 301, E922-E930 (2011).
24. Charbonneau, A. & Marette, A. Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes 59, 861-871 (2010).
25. Xu, E. et al. Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance. Endocrinology 150, 3503-3512 (2009).
26. Mari, A. Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am. J. Physiol. 263, E400-E415 (1992).
27. Mulvihill, E.E. et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes 60, 1446-1457 (2011).
28. Xu, E. et al. Hepatocyte-specific Ptpn6 deletion protects from obesity-linked hepatic insulin resistance. Diabetes 61, 1949-1958 (2012).
29. Chung, J. et al. HSP72 protects against obesity-induced insulin resistance. Proc. Natl. Acad. Sci. USA 105, 1739-1744 (2008). (Pubitemid 351346584)
30. Jenkins, Y. et al. AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes. PLoS ONE 8, e81870 (2013).
31. Moh, A. et al. STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase-3 β. Diabetes 57, 1227-1235 (2008).
32. Ro, A. et al. Reduced liver injury in the interleukin-6 knockout mice by chronic carbon tetrachloride administration. Eur. J. Clin. Invest. 38, 306-316 (2008).
33. Schmittgen, T.D. & Livak, K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1108 (2008). (Pubitemid 351818697)